This Million Targets Drug: A $7M Bet on a CNS Breakthrough
A focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
Choosing no annual fee credit cards can significantly impact your finances. Consider essential factors to ensure you make the best choice.
22,484 articlesA focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
Nvidia has built an AI powerhouse, but its stock sits at a valuation that invites scrutiny. This guide breaks down wh...
In 2026, savvy investors favor dividend stocks that reliably pay and grow. This article highlights two no-brainer div...
A Nurix Therapeutics insider recently sold shares, drawing attention from investors. This article breaks down the mov...
Thinking beyond the U.S. market? This guide explains why ixus: this international stock can play a key role in divers...
A niche investment move places acuta capital erasca (eras) at the center of Erasca's ambitious quest in targeted canc...
When a high-profile investor shifts a crypto position, the market takes notice. mark cuban says sold most of his Bitc...
The idea of a bargain in the cruise sector is enticing, but cheap can be risky. This article breaks down how to judge...
BlackBerry is navigating a pivot from legacy devices to software and security. This guide breaks down what to expect ...
After a staggering 453% surge, investors face a crossroads: take profits now or double down on a company reshaping th...
UnitedHealth Group just 52-week highs spark questions about sustainability. This guide breaks down what's driving the...
When the market opened on Wednesday, Jabil shares surged as investors digested stronger-than-expected Q3 results and ...